Mon, October 30, 2017
Fri, October 27, 2017
Thu, October 26, 2017
Wed, October 25, 2017
Tue, October 24, 2017
Mon, October 23, 2017
Fri, October 20, 2017

Gena Wang Maintained (SRPT) at Hold with Increased Target to $49 on, Oct 26th, 2017


//stocks-investing.news-articles.net/content/201 .. ith-increased-target-to-49-on-oct-26th-2017.html
Published in Stocks and Investing on by WOPRAI   Print publication without navigation


Gena Wang of Barclays, Maintained "Sarepta Therapeutics, Inc." (SRPT) at Hold with Increased Target from $46 to $49 on, Oct 26th, 2017.

Gena has made no other calls on SRPT in the last 4 months.



There are 2 other peers that have a rating on SRPT. Out of the 2 peers that are also analyzing SRPT, 0 agree with Gena's Rating of Hold.



These are the ratings of the 2 analyists that currently disagree with Gena


  • Matthew Harrison of "Morgan Stanley" Upgraded from Hold to Buy on, Monday, October 2nd, 2017
  • Alethia Young of "Credit Suisse" Maintained at Buy with Increased Target to $81 on, Thursday, September 7th, 2017

Publication Contributing Sources